Summary of Evotec Q1 2026 Earnings Call

1Key Financial Results and Metrics

Group Revenues: EUR 156.6 million, a decrease of 21.7% year-over-year, primarily due to the nonrecurrence of a $25 million license sale in Q1 2025 and ongoing market softness.

Adjusted EBITDA: Negative EUR 21.9 million, compared to positive EUR 3.1 million in Q1 2025.

D&PD Revenues: EUR 119.9 million, down 14.7% year-over-year; adjusted EBITDA for D&PD was negative EUR 9.8 million.

Just-Evotec Biologics Revenues: EUR 36.8 million, a decline of 38% year-over-year, impacted by the absence of the prior year's license sale.

Liquidity: Total liquidity stood at EUR 444.8 million, down EUR 31.6 million from the previous quarter, but the company maintains a solid net cash position.

2Strategic Updates and Business Highlights

Horizon Initiative: Evotec has begun implementing its Horizon business transformation plan aimed at operational excellence, scientific leadership, and commercial execution. This includes restructuring and leadership enhancements.

Leadership Changes: Claire Hinshelwood was appointed as CFO, and Ingrid Muller joined as COO to support the Horizon initiative.

Commercial Indicators: Early signs of improvement in customer engagement and partnership pipeline, with increased proposal activity in drug discovery and preclinical development.

Partnerships: Continued progress in collaborations, including new grants from the Gates Foundation for tuberculosis research and advancements in dermatology with Almirall.

3Forward Guidance and Outlook

Full Year 2026 Guidance: Revenues expected between EUR 700 million to EUR 789 million (EUR 730 million to EUR 810 million at constant exchange rates) and adjusted EBITDA between EUR 0 million to EUR 40 million (EUR 10 million to EUR 15 million at constant exchange rates).

Second Half Expectations: Anticipated recovery in market conditions and D&PD demand, with performance improvements expected to be weighted towards the second half of the year.

4Bad News, Challenges, or Points of Concern

Revenue Decline: Significant year-over-year revenue drop due to prior license sales and ongoing market challenges in early drug discovery.

Negative EBITDA: Continued losses in adjusted EBITDA raise concerns about profitability in the near term.

Market Softness: Persistent softness in the D&PD market and foreign exchange headwinds are ongoing challenges.

Leadership Transition: The recent change in CFO could introduce uncertainty during a critical transformation phase.

5Notable Q&A Insights

Confidence in Revenue Growth: Management expressed confidence in achieving full-year guidance, emphasizing that the first quarter's performance aligns with expectations for a gradual recovery in the second half.

Strategic Review: The strategic review is not a response to external pressures but a logical step in the company's transformation process.

Order Book Dynamics: Management indicated that while Q1 revenues were flat compared to Q4, there was a double-digit increase in order intake, suggesting a rebuilding of the order book.

AI Integration: Evotec views AI as a supportive tool in drug discovery rather than a competitive threat, with ongoing demand from AI-first companies contributing to growth. This summary encapsulates the key points discussed during the earnings call, providing a balanced view of Evotec's current financial health, strategic direction, and market outlook.